Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?

Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant.

BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.

Why AstraZeneca Would Consider It

The strategic logic for AstraZeneca, at first glance, centers on its persistent underrepresentation in the United States. The company sourced 42% of its first-half 2026 revenues from the US, compared with 69% for BMY last quarter, according to Jefferies analysis cited by CNBC. AstraZeneca only completed a direct NYSE listing earlier in 2026, underscoring how recently it has been building a domestic US profile. Absorbing BMY would instantly reposition AZN as a top-tier American commercial operation.

There is also pipeline logic. AZN is stronger in solid tumors; BMY's expertise sits in blood cancers and cell therapies. Jefferies described the combined oncology portfolio as potentially the broadest in the industry. For CEO Pascal Soriot, who has spent 14 years quadrupling AstraZeneca's share price and set a target of $80 billion in annual revenue by 2030, a transformative acquisition could accelerate that timeline.

But investors who have followed Soriot's tenure are skeptical precisely because of that record. "Given the strength of AZ's growth and innovation profile, we are a bit perplexed," Jefferies analysts wrote. "If there is one company that doesn't need financial engineering, it's AZ."

Markus Manns, a portfolio manager at Union Investment and an AstraZeneca shareholder, was blunter in comments to Reuters: "A combination with Bristol does not make strategic or financial sense. Many past mega-mergers have destroyed value and there is no apparent need for Astra to do it."

Why BMY May Want a Deal

For Bristol Myers, the calculus is more straightforward. The company faces a looming loss-of-exclusivity cliff on two of its biggest franchises: Eliquis and Opdivo together account for roughly half of BMY's total sales. A merger would give BMY shareholders a premium exit before that revenue erosion accelerates.

BMY's recent earnings actually strengthen its negotiating position. The company posted a Q2 2026 EPS of $2.04 against a $1.61 consensus forecast, a 26.71% beat, alongside revenue of $12.97 billion versus $11.71 billion expected. That result sent the stock near its 52-week high of $68.10 just days before merger reports surfaced.

Pipeline uncertainty, however, complicates a clean valuation. BMY still has pivotal readouts pending for blood thinner milvexian and schizophrenia drug Cobenfy. RBC Capital Markets recently noted that the uncertainty around those programs makes a full pipeline assessment difficult at this stage.

The Antitrust Wall

The central obstacle to any deal is regulatory, and analysts are not mincing words about the severity of the overlap. Both companies compete directly in non-small cell lung cancer: BMY's Opdivo generated $10.05 billion in 2025 sales while AstraZeneca's Imfinzi generated $6.06 billion, according to BioSpace. That is not a peripheral collision; it is head-to-head competition in one of the world's largest oncology markets.

BMO Capital Markets wrote that "based on significant business overlap, we believe a deal is less likely to materialize." BMO also estimates that neither company has the standalone financial firepower to buy the other outright, putting BMY's deal capacity at roughly $32 billion and AZN's at roughly $37 billion, well short of what a $400 billion combination would require.

Antitrust lawyer Andre Barlow of DBM Law Group, speaking to Reuters, said he would "expect a Trump FTC to scrutinize the merger, and if there are significant overlaps in certain drugs and late-stage pipeline overlaps, it would require meaningful divestitures." Barlow added that "bipartisan support to scrutinize pharma deals" means even a lighter-touch administration would press hard on bundling and innovation concerns.

The political dimension extends beyond standard antitrust review. Jefferies flagged that AstraZeneca "would effectively become a UK-based acquirer of one of the largest US pharmaceutical companies, at a time when US politicians are focused on domestic production and strategic sectors," per Pharma Executive. That framing could invite congressional scrutiny well beyond what the FTC would apply on competitive grounds alone.

The historical precedent offers a caution. BMY's own $74 billion acquisition of Celgene in 2019 required the divestiture of psoriasis drug Otezla to clear antitrust review. A deal roughly five times that size, with far greater product overlap, would almost certainly demand a more extensive restructuring of the combined portfolio before any regulator signs off.

Bull Case, Base Case, Bear Case

Bull case: AZN and BMY negotiate a deal structure — likely a large all-share merger — that front-loads divestitures in the NSCLC space, satisfying regulators while preserving the broader oncology and pipeline synergies. BMY shareholders receive a meaningful premium to the current price. AZN uses the combined US commercial infrastructure to pull forward its $80 billion revenue target.

Base case: Talks drag into late 2026 without a definitive agreement. The regulatory complexity and financing gap identified by BMO Capital Markets prove difficult to bridge. Both companies address the rumors on their Q3 earnings calls in late October without committing to a deal. The overhang may depress AZN's valuation through year-end.

Bear case: Talks collapse entirely under shareholder and regulatory pressure. AZN's stock partially recovers as investors price in the standalone growth story, but the episode raises governance questions about strategic discipline. BMY is left without a merger premium and faces its loss-of-exclusivity cliff alone.

Neither AstraZeneca nor BMY has confirmed or denied the talks on the record. The FT's sources said a deal "may never materialize," and no timeline or deal structure has been reported.

Both companies report Q3 earnings in the final week of October, and absent a formal deal announcement, those calls will be the first opportunity for management to speak on the record about whether this $400 billion conversation was real, and whether it still is.

You May Also Be Interested In

• Justice Department halts antitrust cooperation with Canada - report
• Arcosa stockholders approve $150-per-share cash buyout by CRH
• Hyperscale Data plans special Class B stock dividend for shareholders